Lumosa Therapeutics Co., Ltd.

Taipei Exchange 6535.TWO

Lumosa Therapeutics Co., Ltd. Market Capitalization on January 14, 2025: USD 1.36 B

Lumosa Therapeutics Co., Ltd. Market Capitalization is USD 1.36 B on January 14, 2025, a NA change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.
  • Lumosa Therapeutics Co., Ltd. 52-week high Market Capitalization is USD 1.98 B on October 28, 2024, which is 46.38% above the current Market Capitalization.
  • Lumosa Therapeutics Co., Ltd. 52-week low Market Capitalization is USD 887.16 M on December 16, 2024, which is -34.55% below the current Market Capitalization.
  • Lumosa Therapeutics Co., Ltd. average Market Capitalization for the last 52 weeks is USD 1.41 B.
Key data
Date Market Capitalization Share Price Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S)
Market news
Taipei Exchange: 6535.TWO

Lumosa Therapeutics Co., Ltd.

CEO Li Fang Pan
IPO Date July 16, 2015
Location
Headquarters No. 3-2, Park Street
Employees 47
Sector Health Care
Industries
Pharmaceuticals Biotechnology Clinical Trials
Description

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.

StockViz Staff

January 15, 2025

Any question? Send us an email